All In Biotech

Drug Trial Radar · NCT07300267

A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)

A Phase 1, Randomized, Double-Blind, Active Comparator Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Novel Pneumococcal Vaccine in Children

Last checked: Nov 20, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 210 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

210

Planned (sponsor's estimate)

Start

Jan 13, 2026

Primary completion

Oct 24, 2028

Study completion May 25, 2029

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Dec 23, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 2 months, up to 15 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Researchers are looking for new vaccines to prevent pneumococcal disease, which is any infection in the lungs or other parts of the body that is caused by a type of bacteria called Streptococcus pneumoniae. V118C is a new vaccine designed to help prevent disease from Streptococcus pneumoniae bacteria. This study will look at V118C in toddlers and infants. The goal of the study is to learn how safe V118C is for children and how well they tolerate it.

Conditions

  • Pneumococcal Infection

Interventions

  • V118C (Stage 1)Biological

    IM administration of V118C

  • V118C (Stage 2)Biological

    IM administration of V118C

  • PCV20 (Stage 1)Biological

    IM administration of PCV20

  • PCV20 (Stage 2)Biological

    IM administration of PCV20

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Stage 1: Percentage of Participants With Immediate Adverse Events (AEs) Following VaccinationTime frame: Up to approximately 30 minutes postvaccination
  2. Stage 1: Percentage of Participants With Solicited Injection-Site Adverse Events (AEs)Time frame: Up to approximately 7 days postvaccination
  3. Stage 1: Percentage of Participants With Solicited Systemic AEsTime frame: Up to approximately 7 days postvaccination
  4. Stage 1: Percentage of Participants With Unsolicited Systemic or Injection-Site AEsTime frame: Up to approximately 28 days postvaccination
  5. Stage 1: Percentage of Participants With Serious Adverse Events (SAEs)Time frame: Up to approximately 12 months postvaccination
  6. Stage 1: Percentage of Participants With Medically Attended AEs (MAAEs)Time frame: Up to approximately 12 months postvaccination
  7. Stage 2: Percentage of Participants With Immediate AEs Following VaccinationTime frame: Up to approximately 30 minutes after each vaccination
  8. Stage 2: Percentage of Participants With Solicited Injection-Site AEsTime frame: Up to approximately 7 days after each vaccination
  9. Stage 2: Percentage of Participants With Solicited Systemic AEsTime frame: Up to approximately 7 days after each vaccination
  10. Stage 2: Percentage of Participants With Unsolicited Systemic or Injection-Site AEsTime frame: Up to approximately 28 days after each vaccination
  11. Stage 2: Percentage of Participants With SAEsTime frame: Up to approximately 12 months postdose 4
  12. Stage 2: Percentage of Participants With MAAEsTime frame: Up to approximately 12 months postdose 4

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Madera Family Medical Group ( Site 1004)

    Madera, California · Recruiting

  • Acevedo Clinical Research Associates ( Site 1029)

    Miami, Florida · Recruiting

  • University of South Florida-Department of Pediatrics ( Site 1002)

    Tampa, Florida · Recruiting

  • Cotton O'Neil Research Center ( Site 1039)

    Topeka, Kansas · Recruiting

  • University of Louisville, Norton Children's Research Institute ( Site 1005)

    Louisville, Kentucky · Recruiting

  • The Pediatric Center ( Site 1025)

    Columbia, Maryland · Recruiting

  • Saint Louis University Center for Vaccine Development ( Site 1031)

    St Louis, Missouri · Recruiting

  • Child Health Care Associates ( Site 1035)

    East Syracuse, New York · Recruiting

  • Carolina Family Care ( Site 1021)

    Charleston, South Carolina · Recruiting

  • Tribe Clinical Research, LLC-Pediatrics ( Site 1008)

    Greenville, South Carolina · Recruiting

  • Tribe Clinical Research - Spartanburg ( Site 1001)

    Spartanburg, South Carolina · Recruiting

  • Epic Medical Research - Carrollton ( Site 1038)

    Carrollton, Texas · Recruiting

  • Epic Medical Research- Garland ( Site 1017)

    Garland, Texas · Recruiting

  • University of Texas Medical Branch ( Site 1020)

    League City, Texas · Recruiting

  • Pediatric Research of Charlottesville, LLC ( Site 1012)

    Charlottesville, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.